Bryant Furlow

The black box warnings are unlikely to deter clinicians from prescribing CAR-T therapies, largely because these patients frequently have few other options.

Perioperative nivolumab can improve event-free survival in patients with stage II-IIIB non-small cell lung cancer receiving neoadjuvant chemotherapy and surgery, a phase 3 trial suggests.

This review discusses the causes of radiotherapy-induced damage to salivary glands, preventive measures, and treatments in patients who received radiation in the treatment of head and neck cancers.

Age, sex, insurance status, and other factors were associated with receipt of immunotherapy in a study of patients with metastatic bladder cancer.

Researchers investigated the feasibility of using a wearable device to monitor patients with RRMM for CRS after undergoing CAR-T therapy, compared with standard-of-care nurse-recorded monitoring.

A pilot project at a Philadelphia cancer center sought to improve awareness of financial assistance resources for patients with multiple myeloma.

L-asparaginase is a powerful tool in treating acute lymphoblastic leukemia but oncology nurses must be on the look-out for immune hypersensitivity reactions and other serious toxicities, monitoring patients and managing these reactions when they occur.

Researchers explored whether clinical frailty assessment impacts outcomes of CAR-T therapy and whether changes in frailty before and after therapy affect outcomes.

Tacrolimus/methotrexate (Tac/MTX) is standard prophylaxis against GVHD in patients undergoing HSCT.

Researchers report on the rates of CRS and ICANS in patients with relapsed/refractory B-ALL who are treated with brexucabtagene autoleucel.